1. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007,93 (9):1137-46. DOI:10.1136/hrt. 2003.025270

2. Dunlay SM, Roger V.L. Understanding the Epidemic of Heart Failure: Past, Present, and Future. Current Heart Failure Reports. 2014,11 (4):404-15. DOI:10.1007/s11897-014-0220-x

3. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017,18 (1):3-40. DOI:10.18087/rhfj. 2017.1.2346

4. Ponikowski P., Voors AA, Anker SD, Bueno H., Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37 (27):2129-200. DOI:10.1093/eurheartj/ehw128

5. Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAmerica. Circulation. 2017,136 (6):e137-61. DOI:10.1161/CIR. 0000000000000509

6. Hubers SA, Brown N.J. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016,133 (11):1115-24. DOI:10.1161/CIRCULATIONAHA. 115.018622

7. McMurray JJV, Packer M., Desai AS, Gong J., Lefkowitz MP, Rizkala AR et al. Angiotensin - niprilysin Inhibition versus enalapril in heart failure. New EnglandJournal of Medicine. 2014,371 (11):993-1004. DOI:10.1056/NEJMoa1409077

8. Jhund PS, Fu M., Bayram E., Chen C-H, Negrusz-Kawecka M., Rosenthal A. et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) ac cording to age: insights from PARADIGM-HF. European Heart Journal. 2015,36 (38):2576-84. DOI:10.1093/eurheartj/ehv330

9. Solomon SD, Claggett B., Desai AS, Packer M., Zile M., Swedberg K. et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circulation: Heart Failure. 2016,9 (3):e002744. DOI:10.1161/CIRCHEART-FAILURE. 115.002744

10. Kristensen SL, Preiss D., Jhund PS, Squire I., Cardoso JS, Merkely B. et al. Risk Related to Pre - Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction CLINICAL PERSPECTIVE: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation: Heart Failure. 2016,9 (1):e002560. DOI:10.1161/ CIRCHEARTFAILURE. 115.002560

11. Böhm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz MP et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017,38 (15):1132-43. DOI:10.1093/eur-heartj/ehw570

12. Mogensen U. Sunday 28 August 2016. European Heart Journal. 2016,37 (suppl 1 ): 193. DOI:10.1093/eurheartj/ehw432

13. Damman K. Monday, 31 August 2015. European Heart Journal. 2015,36 (suppl 1):509-847. DOI:10.1093/eurheartj/ehv400

14. Desai AS, McMurray JJV Packer M., Swedberg K., Rouleau JL, Chen F. et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015,36(30):1990-7. DOI:10.1093/eurheartj/ehv186